
0:00
2:14
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
More episodes from "Pharmaceutical Executive"



Don't miss an episode of “Pharmaceutical Executive” and subscribe to it in the GetPodcast app.








